Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06213636

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

T-cell Infusion Targeting CD19 and CD22 for Refractory/Relapsed Leukemia/Lymphoma Patients With or Without Central Nervous System Involvement

Sponsor: Essen Biotech

Conditions Acute Lymphoblastic Leukemia, Adult B-Cell Acute Lymphoblastic Leukemia, in Relapse Central Nervous System Lymphoma Diffuse Large B Cell Lymphoma Lymphoma, Follicular MCL Non-Hodgkin Lymphoma, B-cell

Interventions CD19/CD22-CAR T cells

Updated 6 times since 2024 Last updated: Aug 5, 2025 Started: Jul 10, 2024 Primary completion: Feb 10, 2027 Completion: Dec 10, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Acute Lymphoblastic Leukemia, Adult B-Cell and Acute Lymphoblastic Leukemia, in Relapse and is currently actively recruiting participants. Essen Biotech leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Dec 2024 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Feb 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Essen Biotech

Data source: Essen Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China